Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share
Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share
Apollomics Inc. (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses. The PIPE financing included participation from both new and existing investors.
Apollomics Inc.（纳斯达克股票代码：APLM）是一家临床阶段的生物制药公司，正在开发多种抗肿瘤候选药物，以治疗难以治疗和耐药的癌症。该公司今天宣布，在扣除发行费用之前，其私人投资公募股权（“PIPE”）融资的认购协议预计将为公司带来约600万美元的总收益。PIPE的融资包括新老投资者的参与。
Pursuant to the terms of the subscription agreements, Apollomics is selling an aggregate of 19,166,666 Class A ordinary shares at a price of $0.30 per share. The PIPE financing is expected to close on May 8, 2024, subject to satisfaction of customary closing conditions.
根据认购协议的条款，Apollomics将以每股0.30美元的价格共出售19,1666股A类普通股。PIPE融资预计将于2024年5月8日结束，但须满足惯例成交条件。
Apollomics intends to use the net proceeds from the PIPE financing, together with the Apollomics' existing cash, cash equivalents, and marketable securities, to fund its pipeline programs, and for general corporate purposes and working capital.
Apollomics打算使用PIPE融资的净收益以及Apollomics的现有现金、现金等价物和有价证券，为其管道项目提供资金，并用于一般公司用途和营运资金。
译文内容由第三方软件翻译。